thiafeline 2.5 mg film-coated tablets for cats
le vet beheer b.v. - thiamazole - film-coated tablet - 2.5 mg/tablet - thiamazole - cats - miscellaneous
thiafeline 5 mg film-coated tablets for cats
le vet beheer b.v. - thiamazole - film-coated tablet - 5 mg/tablet - thiamazole - cats - miscellaneous
glyxambi 25 mg/5 mg empagliflozin/linagliptin 25mg/5mg film coated tablet blister pack
boehringer ingelheim pty ltd - linagliptin, quantity: 5 mg; empagliflozin, quantity: 25 mg - tablet, film coated - excipient ingredients: purified talc; hypromellose; mannitol; crospovidone; titanium dioxide; magnesium stearate; copovidone; pregelatinised maize starch; macrogol 6000; iron oxide red; maize starch - glyxambi tablets are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties ? clinical trials).
glyxambi 10 mg/5 mg empagliflozin/linagliptin 10mg/5mg film coated tablet blister pack
boehringer ingelheim pty ltd - empagliflozin, quantity: 10 mg; linagliptin, quantity: 5 mg - tablet, film coated - excipient ingredients: iron oxide yellow; macrogol 6000; hypromellose; crospovidone; maize starch; titanium dioxide; mannitol; purified talc; pregelatinised maize starch; copovidone; magnesium stearate - glyxambi tablets are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties ? clinical trials).
lamivudine/zidovudine viatris 150/300 lamivudine 150 mg / zidovudine 300 mg film-coated tablet bottle
alphapharm pty ltd - lamivudine, quantity: 150 mg; zidovudine, quantity: 300 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; propylene glycol; magnesium stearate; sodium starch glycollate type a; titanium dioxide; hypromellose - lamivudine and zidovudine combination tablet is indicated for use alone or in combination with other antiretroviral therapies in the treatment of hiv infection.
femme-tab 20/100 levonorgestrel 100mcg ethinylestradiol 20mcg film-coated tablet blister pack
aft pharmaceuticals pty ltd - levonorgestrel, quantity: 100 microgram; ethinylestradiol, quantity: 20 microgram - tablet, film coated - excipient ingredients: gelatin; macrogol 4000; magnesium stearate; maize starch; lactose monohydrate; titanium dioxide; hypromellose - oral contraception
rispa risperidone 2 mg film-coated tablet blister pack
arrotex pharmaceuticals pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hypromellose; microcrystalline cellulose; propylene glycol; magnesium stearate; titanium dioxide; lactose monohydrate; sunset yellow fcf aluminium lake; sodium lauryl sulfate; purified talc; maize starch - treatment of schizophrenia and related psychoses. . short term treatment of acute mania associated with bipolar 1 disorder. . treatment of behavioural disturbances in dementia. . treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. . treatment of behavioural disorders associated with autism in children and adolescents.
rispa risperidone 0.5 mg film-coated tablet blister pack
arrotex pharmaceuticals pty ltd - risperidone, quantity: 0.5 mg - tablet, film coated - excipient ingredients: titanium dioxide; maize starch; microcrystalline cellulose; hypromellose; purified talc; propylene glycol; sodium lauryl sulfate; iron oxide red; magnesium stearate; colloidal anhydrous silica; lactose monohydrate - treatment of schizophrenia and related psychoses. . short term treatment of acute mania associated with bipolar 1 disorder. . treatment of behavioural disturbances in dementia. . treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. . treatment of behavioural disorders associated with autism in children and adolescents.
rispa risperidone 1 mg film-coated tablet blister pack
arrotex pharmaceuticals pty ltd - risperidone, quantity: 1 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; magnesium stearate; hypromellose; maize starch; microcrystalline cellulose; propylene glycol; lactose monohydrate; purified talc; colloidal anhydrous silica - treatment of schizophrenia and related psychoses. . short term treatment of acute mania associated with bipolar 1 disorder. . treatment of behavioural disturbances in dementia. . treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. . treatment of behavioural disorders associated with autism in children and adolescents.
rispa risperidone 4 mg film-coated tablet blister pack
arrotex pharmaceuticals pty ltd - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; quinoline yellow aluminium lake; propylene glycol; purified talc; indigo carmine aluminium lake; colloidal anhydrous silica; lactose monohydrate; sodium lauryl sulfate; titanium dioxide; hypromellose; magnesium stearate - treatment of schizophrenia and related psychoses. . short term treatment of acute mania associated with bipolar 1 disorder. . treatment of behavioural disturbances in dementia. . treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. . treatment of behavioural disorders associated with autism in children and adolescents.